Model-Informed Precision Dosing of Tacrolimus in Pediatric Kidney Transplantation

Starting soon

Conditions studied: Pediatric Kidney Transplantation

In brief

The purpose of this study is to develop a novel and applicable dosing algorithm that helps support the clinical decision to achieve tacrolimus levels within the optimal immunosuppression range despite sparse sampling in routine clinical practice in pediatric kidney transplantation. This clinical decision support tool (CDST) is based on a hybrid population pharmacokinetics-machine learning approach aiming for tacrolimus dose individualization and reducing the risk of acute graft rejection.

Key facts

Study ID

NCT07549230

Run by

Helwan University

People needed

130

Starts

2026-06-01

Expected to finish

2027-06-01

Last updated by the study team

2026-04-29

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Pediatric patients (< 18 years old).
• First-time kidney transplant recipients who have less than 20% PRA and no DSA.
• Adherent to tacrolimus for a year post-transplantation.
• All data, including therapeutic drug monitoring (TDM) data, are available.

You may not qualify if…

• Non-adherent patients to tacrolimus.
• Unavailable or missing data.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.